BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16805720)

  • 1. Everolimus: an immunosuppressive agent in transplantation.
    Patel JK; Kobashigawa JA
    Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
    Kovarik JM
    Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the proliferation inhibitor everolimus.
    Nashan B
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C; Croom KF
    Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus.
    Chapman TM; Perry CM
    Drugs; 2004; 64(8):861-72; discussion 873-4. PubMed ID: 15059040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation signal inhibitors in cardiac transplantation.
    Gustafsson F; Ross HJ
    Curr Opin Cardiol; 2007 Mar; 22(2):111-6. PubMed ID: 17284989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in liver and lung transplantation.
    Koch M
    Drugs Today (Barc); 2009 Jan; 45(1):11-20. PubMed ID: 19271028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
    N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.
    Neumayer HH
    Transplantation; 2005 May; 79(9 Suppl):S72-5. PubMed ID: 15880019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials.
    Sánchez-Fructuoso AI
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):807-19. PubMed ID: 18611120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H; Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with everolimus.
    Augustine JJ; Hricik DE
    Transplant Proc; 2004 Mar; 36(2 Suppl):500S-503S. PubMed ID: 15041396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of everolimus in chronic allograft nephropathy.
    Das U; Dakshinamurty KV
    Saudi J Kidney Dis Transpl; 2013 Sep; 24(5):910-6. PubMed ID: 24029254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
    Pascual J
    Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.